MAGE-3.A1 Peptide Vaccine(Cliniques Universitaires Saint-Luc)(MAGE-3.A1 Peptide Vaccine(Cliniques Universitaires Saint-Luc))

概要

基本信息

药物类型

合成肽疫苗、治疗性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

转移性黑色素瘤

原研机构

Cliniques Universitaires Saint-Luc

在研机构-

非在研机构

Cliniques Universitaires Saint-Luc

最高研发阶段终止临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 MAGE-3.A1 Peptide Vaccine(Cliniques Universitaires Saint-Luc) 相关的临床试验

NCT01723813 / Terminated临床1/2期IIT

Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma

The purpose of this study is to determine whether the intravenous and/or GM-CT-01 administration can correct Tumor Infiltrating Lymphocytes (TIL) anergy and induce a more efficient and long-lasting anti-tumoral immune response following peptide vaccination.

开始日期2012-04-01

申办/合作机构

Cliniques Universitaires Saint-Luc

100 项与 MAGE-3.A1 Peptide Vaccine(Cliniques Universitaires Saint-Luc) 相关的临床结果

登录后查看更多信息

100 项与 MAGE-3.A1 Peptide Vaccine(Cliniques Universitaires Saint-Luc) 相关的转化医学

登录后查看更多信息

100 项与 MAGE-3.A1 Peptide Vaccine(Cliniques Universitaires Saint-Luc) 相关的专利（医药）

登录后查看更多信息

1

项与 MAGE-3.A1 Peptide Vaccine(Cliniques Universitaires Saint-Luc) 相关的文献（医药）

2007-03-27·Cancer Immunology, Immunotherapy2区 · 医学

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

2区 · 医学

Article

作者: Thierry Boon ; Francis Brasseur ; Danièle Godelaine ; Javier Carrasco ; Kris Thielemans ; Aline Van Pel ; Bart Neyns

A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.

100 项与 MAGE-3.A1 Peptide Vaccine(Cliniques Universitaires Saint-Luc) 相关的药物交易

登录后查看更多信息